Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $6.8750.

Several research analysts have recently weighed in on the stock. Alliance Global Partners assumed coverage on shares of Sensus Healthcare in a report on Friday, March 6th. They set a “buy” rating and a $7.50 price objective on the stock. Citigroup reiterated a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Wall Street Zen lowered shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Maxim Group dropped their target price on shares of Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a research report on Tuesday, April 21st.

Institutional Trading of Sensus Healthcare

Institutional investors and hedge funds have recently bought and sold shares of the business. Pacific Ridge Capital Partners LLC boosted its stake in shares of Sensus Healthcare by 21.8% during the 4th quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock valued at $2,781,000 after buying an additional 125,245 shares during the last quarter. Divisadero Street Capital Management LP boosted its stake in Sensus Healthcare by 39.5% during the 3rd quarter. Divisadero Street Capital Management LP now owns 452,897 shares of the company’s stock valued at $1,422,000 after acquiring an additional 128,224 shares during the last quarter. Geode Capital Management LLC boosted its stake in Sensus Healthcare by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 158,240 shares of the company’s stock valued at $630,000 after acquiring an additional 5,316 shares during the last quarter. Sachetta LLC boosted its stake in Sensus Healthcare by 6.8% during the 4th quarter. Sachetta LLC now owns 148,508 shares of the company’s stock valued at $591,000 after acquiring an additional 9,500 shares during the last quarter. Finally, Greenline Wealth Management LLC bought a new position in Sensus Healthcare during the 4th quarter valued at $513,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

Sensus Healthcare Price Performance

Shares of SRTS stock opened at $3.19 on Friday. The firm has a market cap of $52.51 million, a P/E ratio of -6.79 and a beta of 1.19. Sensus Healthcare has a 1-year low of $2.82 and a 1-year high of $5.92. The firm’s 50-day simple moving average is $3.94 and its 200-day simple moving average is $4.16.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The company had revenue of $3.39 million for the quarter, compared to analysts’ expectations of $5.32 million. Sensus Healthcare had a negative return on equity of 15.79% and a negative net margin of 34.50%.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.